Dermatologic Therapy最新文献

{"title":"Dermoscopic Signs Correlated With Demodex Density in Rosacea: A Comparative Analysis With Reflectance Confocal Microscopy","authors":"Yajing Cao, Xidie Yin, Xiaojing Liu, Hongyan Xu, Chan Hu, Yutong Yang, Qingyu Zeng, Shiyi Chen, Xiuli Wang, Peiru Wang","doi":"10.1155/dth/4555257","DOIUrl":"https://doi.org/10.1155/dth/4555257","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p><i>Demodex</i> mites are closely associated with the pathogenesis and progression of rosacea. Reflectance confocal microscopy (RCM) is a highly reliable, noninvasive tool for the in vivo qualitative and quantitative assessment of <i>Demodex</i> density, whereas dermoscopy is a convenient and widely used adjunctive technique for evaluating inflammatory skin diseases. However, the correlation between dermoscopic manifestations and RCM-quantified <i>Demodex</i> burden in rosacea remains insufficiently clarified, and evidence regarding dermoscopic indicators for identifying <i>Demodex</i> infestation is limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to systematically analyze the correlation between typical dermoscopic features and RCM-verified <i>Demodex</i> density in Chinese patients with rosacea and to summarize reliable dermoscopic signs for evaluating <i>Demodex</i> infestation across different rosacea subtypes, using RCM-based quantitative assessment as the reference standard.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 97 patients clinically diagnosed with rosacea were enrolled. All patients underwent standardized dermoscopic examination and RCM imaging. RCM was used to quantitatively assess follicular <i>Demodex</i> density and to classify patients into <i>Demodex</i>-positive and <i>Demodex</i>-negative groups. Comparative analyses were performed to identify dermoscopic characteristics that differentiated groups with different <i>Demodex</i> burdens and to further explore dermoscopic correlates of <i>Demodex</i> infestation in the erythematotelangiectatic and papulopustular rosacea subtypes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>RCM assessment identified <i>Demodex</i> positivity in 69.1% of patients with rosacea, with positive rates of 47.6% in the erythematotelangiectatic rosacea and 85.5% in the papulopustular rosacea. Based on RCM quantification, the <i>Demodex</i>-positive group showed significantly higher frequencies of perifollicular vessels, globular vessels, yellow scales, follicular plugs, follicular pustules, perifollicular erythema, and red amorphous areas on dermoscopy. In erythematotelangiectatic rosacea, dermoscopic features including perifollicular vessels, yellow scales, follicular plugs, and perifollicular erythema were associated with RCM-confirmed <i>Demodex</i> infestation. In papulopustular rosacea, increased perifollicular vascularity and the presence of red amorphous areas on dermoscopy corresponded to higher <i>Demodex</i> density confirmed by R","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4555257","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148752734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of Periorbital Wrinkles With 1565-nm Fractional Er:Glass Laser in Asian Patients","authors":"Hongjie Zheng,&nbsp;Zhuoxuan Jia,&nbsp;Bijun Kang,&nbsp;Yizuo Cai,&nbsp;Qian Yu,&nbsp;Yichen Zhang,&nbsp;Wenjie Zhang,&nbsp;Wei Li","doi":"10.1155/dth/4721999","DOIUrl":"https://doi.org/10.1155/dth/4721999","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Periorbital wrinkles are among the earliest signs of facial aging.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study evaluates the efficacy, safety, and associated histological changes of 1565-nm Er:glass nonablative fractional laser (NAFL) for periorbital wrinkle reduction.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this assessor-blinded, prospective, split-face randomized study, 20 Asian patients received 5 sessions of 1565-nm NAFL on one periorbital side at 4-week intervals. Wrinkle severity was assessed via the Fitzpatrick Wrinkle Classification System (FWCS), standardized photograph-based wrinkle length measurements, and wrinkle reduction rate. Transepidermal water loss (TEWL), pain visual analog scale (VAS), patient satisfaction (LSS), and adverse events were recorded. A parallel animal study (<i>n</i> = 9) was performed to evaluate histological changes after treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the clinical study, the treated side showed significant improvement in periorbital wrinkles, with the FWCS score decreased from 3.23 ± 1.10 at baseline to 2.09 ± 1.00 at 3 months after treatment (<i>p</i> &lt; 0.001). Standardized photograph-based assessment showed a mean wrinkle length reduction of 14.60% on the treated side. No severe adverse events were reported, and TEWL remained stable from baseline to the 3-month follow-up. The animal study showed increased epidermal and dermal thickness and collagen deposition in treated skin.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The 1565-nm Er:glass NAFL may be an effective and safe treatment for improving mild-to-moderate periorbital wrinkles in young Asian adults, with supportive histological evidence of epidermal and dermal remodeling.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4721999","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148752376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pemphigus Patients Receiving Rituximab: Latent Tuberculosis Risk and Diagnostic Concordance Between Tuberculin Skin Test and Interferon-Gamma Release Assay","authors":"Fateme Faramarzirad,&nbsp;Azin Tahvildari,&nbsp;Nastaran Namazi,&nbsp;Fahimeh Abdollahimajd,&nbsp;Nabaa Al-Zubaidi,&nbsp;Sahar Dadkhahfar","doi":"10.1155/dth/5595483","DOIUrl":"https://doi.org/10.1155/dth/5595483","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background and Aim&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Rituximab (RTX) therapy in pemphigus patients necessitates reliable latent &lt;i&gt;tuberculosis&lt;/i&gt; (TB) infection (LTBI) screening to prevent reactivation. The tuberculin skin test (TST) and Interferon-Gamma Release Assay (IGRA) are commonly used, yet discrepancies in their results create uncertainty, particularly in immunocompromised hosts. Evidence regarding their concordance in pemphigus patients undergoing RTX is limited. This study evaluates the agreement between TST and IGRA and explores whether TST alone can serve as an effective LTBI screening tool before RTX treatment.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A multicenter prospective observational study was conducted on adult pemphigus patients confirmed through biopsy/immunofluorescence. Baseline evaluation included demographic and disease data, IGRA, TST, and chest X-ray. RTX was given as either 500 mg weekly for 4 weeks or 1000 mg every 2 weeks for two doses. Six months later, IGRA, TST, chest imaging, and clinical TB assessment were repeated. Data were analyzed with SPSS v26, using McNemar’s exact test for paired comparisons, generalized estimating equations for repeated measures within subjects, and Cohen’s kappa (McHugh’s criteria) for test agreement.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Forty-two patients with pemphigus (92.9% pemphigus vulgaris, 7.1% pemphigus foliaceus; mean age = 51.98 ± 13.47 years; 52.4% female) were followed for a mean duration of 10.1 ± 3.66 months. All had a history of prior BCG vaccination, were asymptomatic for TB at baseline, and demonstrated normal chest radiographs. Four patients (9.8%) were diagnosed with LTBI by IGRA and/or TST and received isoniazid prophylaxis before initiation of RTX therapy. At 6 months post-RTX, no cases of clinical or radiographic TB were detected. IGRA and TST positivity rates remained unchanged (&lt;i&gt;p&lt;/i&gt; = 1.00), except for one patient who reverted from positive to negative (OR = 1.37). TST results were stable (&lt;i&gt;p&lt;/i&gt; = 1.00). IGRA–TST agreement was moderate before (&lt;i&gt;κ&lt;/i&gt; = 0.64) and after therapy (&lt;i&gt;κ&lt;/i&gt; = 0.79) with no significant directional bias on positivity rate.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;RTX treatment in pemphigus patients, following appropriate latent TB screening and preventive therapy, was not associated with TB reactivation. IGRA and TST results remained stable after treatment, with sustained agreement between the tests. These findings support the safety of RTX and the potential for utility of either method for TB screening in BCG-vaccinated","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5595483","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148752377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Safety During Biologic Therapy for Psoriasis: A Class-Wide Systematic Review and Meta-Analysis","authors":"Mária Veronika Kolonics,&nbsp;Katalin Martyin,&nbsp;Noémi Ágnes Galajda,&nbsp;Fanni Adél Meznerics,&nbsp;Adib Abed,&nbsp;Karen Krisztina Fazekas,&nbsp;Máté Krebs,&nbsp;Ákos Ungvári,&nbsp;Anna Czibulya,&nbsp;Péter Kulyassa,&nbsp;Lajos Vince Kemény,&nbsp;Norbert Kiss,&nbsp;Péter Hegyi,&nbsp;András Bánvölgyi,&nbsp;Péter Holló","doi":"10.1155/dth/8514168","DOIUrl":"https://doi.org/10.1155/dth/8514168","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Psoriasis is an immune-mediated inflammatory disease (IMID) with elevated cardiovascular (CV) risk. Biological therapies for psoriasis are highly effective and have a favourable safety profile; nevertheless, studies have suggested that some therapeutical agents may increase the risk of major adverse cardiovascular events (MACEs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To clarify CV safety across all four biologic classes used in psoriasis by quantifying MACE and related outcomes by conducting a systematic review and meta-analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systematic search up to November 2024 was conducted for randomised and nonrandomised studies of tumour necrosis factor inhibitors, interleukin (IL)-12/23, IL-17 and IL-23 inhibitors in psoriasis. Outcomes were MACE, myocardial infarction (MI), ischaemic stroke, CV mortality (CVM) and heart failure (HF). Pooled proportions with 95% confidence intervals (CIs) were calculated by class.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>127 studies were included, comprising 67,344 patients. Across all biologic classes, pooled proportions for MACE (0.0015–0.0041), MI (0.0017–0.0046), stroke (0.0003–0.0023), CVM (0.0005–0.0011) and HF (0.0016–0.0065) were low.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Biological therapies for psoriasis showed low CV event rates across all four biologic classes, with no indication of increased CV risk. These findings support their CV safety, although further long-term studies in high-risk populations are warranted.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8514168","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148647726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Skin Microbiome Depletion on Langerhans Cells and Regulatory T Cells in Murine Contact Hypersensitivity","authors":"Haixia Feng,&nbsp;Yufeng Liu,&nbsp;Qing Guo,&nbsp;Shuhong Sun,&nbsp;Changxu Han,&nbsp;Zhenying Zhang","doi":"10.1155/dth/5859908","DOIUrl":"https://doi.org/10.1155/dth/5859908","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aimed to investigate the effects of topical antibiotics on skin microflora and cutaneous inflammation and to explore the association between the skin microbiome and contact hypersensitivity (CHS) in mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Topical antibiotics were applied to Balb/c mice to deplete the skin microbiome. Then, a CHS model was established, and ear swelling and tissue inflammation were compared. For the immunophenotypic analysis, the numbers of Langerhans cells (LCs) and regulatory T cells (Treg) in skin-draining lymph nodes were quantified by flow cytometry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>(1) Influence of the skin microbiome on the CHS model: Topical application of mupirocin on the healthy skin of mice showed no alteration in the skin organizational structure, and there was no sign of inflammation. However, the number of skin bacterial colonies after tissue culture was much lower than that of the control. The ear swelling of the oxazolone-induced CHS model in the mupirocin group, fusidic acid group, and neomycin sulfate group was markedly greater than that in the emulsion base group. The ear swelling in the mupirocin group, after sensitization by oxazolone, DNFB, or TNCB, respectively, was much greater than that in the emulsion base group. These data indicated that the reduction of the skin microbiome was associated with exacerbated CHS responses. (2) Changes related to the effect of the skin microbiome on CHS: The number of LCs in skin-draining lymph nodes in the mupirocin group was higher than that in the emulsion base group after sensitization. The number of Tregs in skin-draining lymph nodes in the mupirocin group was higher than that in the emulsion base group after sensitization. These data indicated that elevated LC counts are accompanied by increased Treg levels, implying a potential association between these two cell types during the sensitization process. However, establishing a direct causal relationship between LCs and Tregs requires further validation using LC-deficient models or functional blockade experiments targeting LCs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Reduction of skin-resident bacteria is associated with exacerbated CHS responses in mice, in association with increased LCs and Tregs in skin-draining lymph nodes. Skin commensals play a critical role in regulating cutaneous immune reactivity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5859908","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regimen of Poly-L-Lactic Acid Injections via Electronic Microneedles for Skin Rejuvenation in Photoaged Skin","authors":"Jing-Ting Zhao,&nbsp;Xiu-Hao Guan,&nbsp;Ze-Yu He,&nbsp;Yuan-Hong Li,&nbsp;Yuan-Yuan Xu,&nbsp;Cheng-Cheng Liu,&nbsp;Li-Li Zhu,&nbsp;Xue-Gang Xu","doi":"10.1155/dth/1501169","DOIUrl":"https://doi.org/10.1155/dth/1501169","url":null,"abstract":"<p>This study evaluated the clinical efficacy and safety of electronic microneedle injection of poly-L-lactic acid (PLLA) for skin rejuvenation in women with photoaged skin. Conducted over 48 weeks at a single center, the prospective, randomized split-face study involved 20 female patients, each receiving PLLA on one side of the face and 0.9% normal saline on the other. Assessments were made at multiple intervals posttreatment, including objective digital skin analysis and histopathological examination, as well as subjective feedback via the Face-Q questionnaire. The results demonstrated significant improvements in skin texture, wrinkles, and pore size on the PLLA-treated side, with histological evidence of collagen thickening and new collagen formation. Significant pore size improvement was first observed at 12 weeks postinjection (PLLA: −0.437 ± 0.037 vs. normal saline: −0.022 ± 0.029, <i>p</i> = 0.031). Wrinkle reduction appeared even earlier, with a significant difference noted at 4 weeks (PLLA: −0.798 ± 0.377 vs. normal saline: −0.112 ± 0.245, <i>p</i> = 0.028). Face-Q responses indicated high patient satisfaction, with a peak satisfaction rate of 89% on the PLLA-treated side. Adverse reactions were minimal and manageable, with no serious events during the follow-up period. These findings suggest that repeated PLLA injections through electronic microneedles significantly enhance skin quality, supporting their potential use in clinical skin rejuvenation. Further research is necessary to optimize treatment protocols and validate long-term benefits.</p><p><b>Trial Registration:</b> Medical Research Registration Information System: MR-21-24-020712</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1501169","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xeligekimab in Chinese Patients With Plaque Psoriasis: Real-World Evidence Including Within-Class IL-17 Inhibitor Switching","authors":"Xi Duan,&nbsp;Shuang Cao,&nbsp;Jianxin Xia,&nbsp;Zongjunlin Liu,&nbsp;Tianhong Xu,&nbsp;Xincai Xiong","doi":"10.1155/dth/7121134","DOIUrl":"https://doi.org/10.1155/dth/7121134","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Xeligekimab, a novel <i>IL-17A</i> inhibitor, demonstrated robust efficacy in Phase 3 trials for moderate-to-severe plaque psoriasis. Real-world evidence in Chinese patients remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective, multicenter observational study, reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement, evaluated 97 patients (18 patients with prior <i>IL-17</i>i experience) with moderate-to-severe plaque psoriasis who initiated xeligekimab between August 2024 and October 2025. The primary endpoint was Physician’s Global Assessment (PGA) 0/1 at Week 12. Secondary endpoints included PASI 75/90/100 responses and Dermatology Life Quality Index (DLQI) 0/1 at Weeks 4, 12, and 24.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The primary endpoint was achieved by 85.6% (95% CI: 77.2%–91.2%) of patients. PGA 0/1 rates were 34.0%, 85.6%, and 92.8% at Weeks 4, 12, and 24. PASI 100 increased from 19.6% to 73.2% across time points. DLQI 0/1 was achieved by 87.6% at Week 24. Among 18 patients with prior <i>IL-17</i> inhibitor exposure, the Week 12 PGA 0/1 response remained robust at 83.3%. In biologic-naïve patients, disease duration ≤ 2 years predicted faster early response (Week 4 PASI 75: 78.6% vs. 42.2%, <i>p</i> = 0.014), though responses converged by Week 12.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Xeligekimab demonstrates substantial real-world effectiveness in Chinese patients with moderate-to-severe plaque psoriasis, including those with prior <i>IL-17</i> inhibitor exposure.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7121134","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148647725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Frequency of Fibromyalgia in Rosacea: Sleep Quality and Depression as Major Drivers of Disease Burden in a Controlled Cross-Sectional Study","authors":"Kismet Kaya,&nbsp;Mahir Digis,&nbsp;Gunseli Acet Karaca,&nbsp;Yunus Gural,&nbsp;Betul Demir","doi":"10.1155/dth/5211362","DOIUrl":"https://doi.org/10.1155/dth/5211362","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Rosacea is a chronic inflammatory dermatosis associated with systemic and psychosocial comorbidities. While a link to psychiatric distress has been established, its relationship with central sensitization syndromes remains unclear. We aimed to determine the prevalence of fibromyalgia syndrome (FMS) in patients with rosacea and investigate the potential contributions of sleep quality, fatigue, depression, and anxiety to disease burden and FMS severity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This cross-sectional study included 54 patients with rosacea and 51 age- and sex-matched healthy controls. Participants were assessed using the 2010 American College of Rheumatology (ACR) criteria for FMS. Disease burden and psychological status were evaluated using the Fibromyalgia Impact Questionnaire (FIQ), Hospital Anxiety and Depression Scale (HADS), Pittsburgh Sleep Quality Index (PSQI), and Fatigue Severity Scale (FSS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The prevalence of FMS was significantly higher in patients with rosacea than in controls (68.5% vs. 9.8%; <i>p</i> &lt; 0.001; OR = 20.02; 95% CI: 6.75–59.37). Patients with rosacea exhibited significantly higher anxiety, depression, and functional disability scores (all <i>p</i> &lt; 0.05)<i>.</i> Multivariate regression analysis identified depression (<i>β</i> = 1.963, <i>p</i> &lt; 0.001) and poor sleep quality (<i>β</i> = 2.364, <i>p</i> &lt; 0.001) as the strongest independent predictors of FMS severity, explaining 48% of the variance (<i>R</i>² = 0.48). Fatigue was the only independent predictor of FMS (OR = 7.17, <i>p</i> = 0.013). ROC analysis showed high discriminative performance for fatigue (AUC = 0.851) and for sleep quality (AUC = 0.816). Phenotypically, subjective dryness was significantly associated with the erythematotelangiectatic rosacea (ETR) subtype (<i>p</i> = 0.009) but less common in the papulopustular rosacea (PPR) subtype (<i>p</i> = 0.024).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Patients with rosacea harbor a substantial burden of undiagnosed FMS, driven primarily by fatigue, sleep disturbance, and depressive symptoms rather than cutaneous severity alone. The distinct association between dryness and the erythematotelangiectatic subtype suggests a subtype-specific sensory profile. Dermatologists should consider screening for sleep and mood disorders to manage the systemic symptom burden in patients with rosacea.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5211362","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148617190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of High-Dose Pulsed Hyaluronidase in Ischemia Following Hyaluronic Acid Fillers: A Retrospective Study of 47 Patients","authors":"Shahriar Nazari,&nbsp;Nima Hadadian,&nbsp;Elham Rezaei,&nbsp;Farzad Pakdel,&nbsp;Nabil Fakih-Gomez,&nbsp;Mohammad Reza Pourani","doi":"10.1155/dth/4216212","DOIUrl":"https://doi.org/10.1155/dth/4216212","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hyaluronic acid (HA) injections, primarily used as dermal fillers, have become popular over the past 2 decades. However, filler injections can lead to severe complications, such as ischemia, with hyaluronidase (HYAL) being the primary treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The study aimed to evaluate the effects of the high-dose pulsed hyaluronidase (HDPH) protocol, which involves administering repeated doses of HYAL exceeding 500 IU.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective observational study was conducted in a private clinic between 2018 and 2023, analyzing 47 cases divided into two groups: Group A, treated with the HDPH protocol, and Group B, which served as the natural history comparison cohort illustrating outcomes associated with delayed presentation and received the palliative therapeutic regimen.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In Group A (<i>n</i> = 29), advanced ischemia was significantly associated with scar formation (<i>p</i> = 0.01). Patients treated with HDPH (Group A) had a lower rate of scar formation (13.8%), while all receiving palliative therapies experienced scar formation (Group B) (100%). Overall, the HDPH protocol is associated with reduced scar formation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study highlights the potential role of the HDPH protocol in the management of ischemia. Early administration of HDPH improves clinical outcomes, highlighting the importance of physician training in its application for vascular-related ischemia. Routine follow-up after filler injections is essential for the early detection and timely treatment of ischemia.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4216212","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Photobiomodulation Therapy With Cord Blood–Derived Platelet-Rich Plasma or Picosecond Laser for Melasma: A Split-Face Study","authors":"Nana Sun,&nbsp;Chenjie Zheng,&nbsp;Zifeng Gong,&nbsp;Shimin Xiong,&nbsp;Zhimin Yang,&nbsp;Shanrong Chen,&nbsp;Ni Zeng","doi":"10.1155/dth/8137319","DOIUrl":"https://doi.org/10.1155/dth/8137319","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Melasma is a prevalent, cosmetically, and psychologically distressing pigmentary disorder. Combination therapies offer promising management strategies. Photobiomodulation therapy (PBMT) modulates melanogenesis and vascular components noninvasively. Cord blood–derived platelet-rich plasma (CB-PRP), rich in growth factors and anti-inflammatory molecules, may enhance melanin suppression and skin repair. Picosecond lasers effectively target pigment particles and melanocytes.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In this prospective, randomized, split-face study, 28 female melasma patients were enrolled (26 completed). All participants received whole-face PBMT bilaterally. One randomly assigned facial side received adjunctive CB-PRP injections; the contralateral side received adjunctive picosecond laser treatment. Outcomes were assessed using the modified Melasma Area and Severity Index (mMASI), VISIA-CR analysis, and patient satisfaction at baseline, 2 weeks, 3 months, and 6 months post-treatment. Statistical analysis was performed using generalized linear mixed models (GLMMs) with the Bonferroni correction.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Both sides showed significant mMASI reductions post-treatment, with the PBMT + CB-PRP side decreasing by 38.3% and the PBMT + picosecond laser side by 38.0% at 6 months (both &lt;i&gt;p&lt;/i&gt; &lt; 0.001 for within-group changes). No significant between-group differences in mMASI were observed at any time point (Bonferroni-corrected &lt;i&gt;p&lt;/i&gt; &gt; 0.05 for all comparisons). GLMM analysis confirmed a significant time main effect (Wald &lt;i&gt;χ&lt;/i&gt;&lt;sup&gt;2&lt;/sup&gt; = 154.800, &lt;i&gt;p&lt;/i&gt; &lt; 0.001) with no significant group × time interaction (&lt;i&gt;p&lt;/i&gt; = 0.943). For VISIA-CR parameters, both sides showed significant improvements in pores (&lt;i&gt;p&lt;/i&gt; &lt; 0.001 for time effect), with no significant between-group differences for any of the eight measured parameters at any follow-up time point (all Bonferroni-corrected &lt;i&gt;p&lt;/i&gt; &gt; 0.05). The PBMT + CB-PRP side showed significant within-group improvements in spots and brown spots (&lt;i&gt;p&lt;/i&gt; &lt; 0.05), whereas the PBMT + picosecond laser side did not; however, direct between-group comparisons for these parameters did not reach statistical significance. Patient satisfaction rates were 88.5% (PBMT + CB-PRP side) and 80.8% (PBMT + picosecond laser side). No serious adverse events occurred in either group.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;PBMT combined with either CB-PRP or picosecond laser significantly improved melasma, with compara","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8137319","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}